GlassScriptPhysician profile
Nehal Shah
NPI 1376006742
$8,445.42
in general payments reported to CMS, 2019-2025
24 companies · $2,534 in 2025
The $2,534 reported for 2025 was more than what 81% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,207 · 2023: $1,689 · 2024: $3,015 · 2025: $2,534.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,075 · Education: $163.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,075.20 |
| Education | $162.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,311.09 | 2022-2025 | Skyrizi, Rinvoq |
| Janssen Biotech, INC. | $1,033.24 | 2022-2025 | Tremfya |
| Lilly USA, LLC | $904.46 | 2022-2025 | Taltz, Olumiant, Ebglyss |
| Arcutis Biotherapeutics, INC. | $754.64 | 2023-2025 | Zoryve |
| Incyte Corporation | $571.27 | 2022-2025 | Opzelura |
| Ucb, INC. | $485.15 | 2022-2025 | Bimzelx, Cimzia |
| Pfizer INC. | $382.38 | 2022-2025 | |
| Dermavant Sciences, INC. | $374.12 | 2023-2024 | Vtama |
| Genzyme Corporation | $360.88 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $344.75 | 2023-2025 | Spevigo, Cyltezo |
| Novartis Pharmaceuticals Corporation | $323.67 | 2023-2025 | |
| E.R. Squibb & Sons, L.L.C. | $238.43 | 2022-2025 | Sotyktu |
| Regeneron Healthcare Solutions, INC. | $219.79 | 2022-2025 | Dupixent |
| Epi Health, LLC | $218.73 | 2022 | |
| Leo Pharma INC. | $178.48 | 2024-2025 | Adbry, Anzupgo |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $177.77 | 2024-2025 | Otezla, Otezla |
| Galderma Laboratories, L.P. | $152.98 | 2024-2025 | Nemluvio |
| Sun Pharmaceutical Industries INC. | $148.14 | 2022-2025 | Absorica Ld, Winlevi, Ilumya |
| Journey Medical Corporation | $118.25 | 2022-2025 | |
| Organon LLC | $50.69 | 2025 | Vtama |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $31.28 | 2023 | Siliq |
| Biofrontera INC. | $28.76 | 2022 | |
| Botanix Sb INC | $20.29 | 2025 | Sofdra |
| Helsinn Therapeutics (U.S.), INC. | $16.18 | 2024 | Valchlor |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nehal Shah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.